Introduction
============

Change is the most fundamental characteristic of biomarkers. Urine can be a better non-invasive source for biomarker discovery since it accumulates many changes ([@ref-10]). Changes introduced into the blood can be more sensitively detected in urine ([@ref-22]). As summarized in a recent paper ([@ref-12]), in some previous biomarker studies, several potential biomarkers perform even better in urine than in blood ([@ref-17]; [@ref-32]; [@ref-43]). Urine proteome is affected by many factors such as age, gender, lifestyle and others. As a result, despite the advantage of urine as a better biomarker source, urine biomarker research can be difficult; changes in urine make sorting out factors directly associated with any particular condition much too complex, especially in human samples ([@ref-10]). Minimizing the confounding factors by using an animal model was illustrated in renal diseases ([@ref-13]; [@ref-46]). In fact, although the number of factors that can affect the urine proteome is still unknown, a better understanding of those factors' effects on urine proteome can help to speed up biomarker discovery. It has been proposed that only changes of the stable components in urine proteome are more likely to become biomarkers ([@ref-36]). Other physiological factors such as water loading, sodium loading, cigarette smoking, diuretics and anticoagulants were found to change urine proteome as well ([@ref-2]; [@ref-23]; [@ref-38]).

The effects of medications on urine proteome also tend to be neglected when clinical experiments were designed. The patients-medicine, healthy-no medicine associations exist in all of the clinical biomarker studies. Therefore "pharmuromics," which studies the effects of medicine on urine, was proposed ([@ref-11]). Anesthetic is commonly used in animal experiments, as well as surgery. However, the effects of anesthetics on urine proteome are not usually considered. It is not clear whether anesthesia affects the urine proteome. In this study, the effects of pentobarbital sodium and chloral hydrate anesthesia on rat urine proteome were studied using liquid chromatography--tandem mass spectrometry (LC-MS/MS).

Materials and Methods
=====================

Experiment animals
------------------

Rats were purchased from the Institute of Laboratory Animal Science, Chinese Academy of Medical Science & Peking Union Medical College. The experiment was approved by Institute of Basic Medical Sciences Animal Ethics Committee, Peking Union Medical College (Animal Welfare Assurance Number: ACUC-A02-2013-015). All animals were kept with standard laboratory diet under controlled indoor temperature (22 ± 1 °C) and humidity (65--70%). The study was performed according to guidelines developed by Institutional Animal Care and Use Committee of Peking Union Medical College.

Rat models
----------

Twelve male Sprague-Dawley rats (weight = 200 g) were divided into two groups. One group was anesthetized by intraperitoneal injection of pentobarbital sodium (*n* = 6, 50 mg/kg), and the other group was by chloral hydrate (*n* = 6, 300 mg/kg). Urine samples before anesthesia were collected as control (about 2 mL). Anesthesia affected urine was collected for three hours during anesthesia (about 2 mL). Anesthesia was supported for four hours and the activities of the anesthetics were detected by measuring muscle relaxation. The urinary protein and creatinine concentration were measured at the Peking Union Medical College Hospital. The self-controlled experiment was conducted in two phases: for the discovery phase, differential protein identification was performed in three independent rats each group; for the validation phase, samples were obtained from the three remaining rats.

Sample preparation
------------------

Urine was centrifuged at 2,000 g for 30 min immediately after collection. Three volumes of acetone were added after removing the pellets and precipitated at 4 °C. Then, lysis buffer (8 M urea, 2 M thiourea, 25 mM dithiothreitol and 50 mM Tris) was used to re-dissolve the pellets. Proteins were digested by trypsin (Trypsin Gold, Mass Spec Grade, Promega, Fitchburg, Wisconsin, USA) using filter-aided sample preparation methods ([@ref-42]). Briefly, after proteins were loaded on the filter unit (Pall, Port Washington, New York, USA), UA buffer (8 M urea in 0.1 M Tris--HCl, pH 8.5) and 50 mM NH~4~HCO~3~ was added. Proteins were denatured at 50 °C for 1 h by the addition of 20 mM dithiothreitol and alkylated in the dark for 40 min by the addition of 50 mM iodoacetamide. Proteins were digested by trypsin (1:50) at 37 °C overnight. The digested peptides were desalted using Oasis HLB cartridges (Waters, Milford, Massachusetts, USA).

LC-MS/MS analysis
-----------------

The digested peptides were dissolved in 0.1% formic acid and loaded on a Michrom Peptide Captrap column (MW 0.5--50 kD, 0.5 × 2 mm; Michrom Bioresources, Auburn, California, USA). The eluent was transferred to a reversed-phase microcapillary column (0.1 × 150 mm, packed with Magic C18, 3 µm, 200 Å; Michrom Bioresources, Auburn, California, USA) by an Agilent 1200 HPLC system. Peptides were analyzed by a LTQ-OrbitrapVelos mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). The LTQ-OrbitrapVelos was operated in data-dependent acquisition mode. Survey MS scans were acquired in the Orbitrap using a 300--2,000 m/z range with the resolution set to 60,000. The 20 most intense ions per survey scan were selected for collision-induced dissociation fragmentation, and the resulting fragments were analyzed in the LTQ. Dynamic exclusion was employed with a 60 s window to prevent the repetitive selection of the same peptide.

Data analysis
-------------

All MS/MS spectra were analyzed using the Mascot search engine (version 2.4.1, Matrix Science, London, UK), and proteins were identified by searching against the Swissprot\_ 2013\_ 07 database (taxonomy: Rattus; containing 9,354 sequences). The parameters were set as follows: carbamidomethylation of cysteines was set as a fixed modification, and oxidation of methionine and protein N-terminal acetylation were set as variable modifications. Trypsin was set as the digestion enzyme, and two missed trypsin cleavage sites were allowed. The precursor mass tolerance was set to 10 ppm, and the fragment mass tolerance was set to 0.5 Da. Peptide and protein identifications were validated by Scaffold (version 4.0.1, Proteome Software Inc., Portland, Oregon, USA). Peptide identifications were accepted if they could be detected with ≥95.0% probability by the Scaffold local false discovery rate algorithm, and protein identifications were accepted if they could be detected with ≥99.0% probability and contained at least 2 identified peptides ([@ref-29]). The acquired raw files were loaded to Progenesis LC-MS/MS software (version 4.1, Nonlinear, Newcastle upon Tyne, UK), and label-free quantification was conducted as previously described ([@ref-15]). For quantification, all peptides (with Mascot score \>30 and *p* \< 0.01) of an identified protein were included.

Western blot analysis
---------------------

Urine proteins were prepared as described in Materials and Methods; 20 µg of each sample were separated by 10% SDS-PAGE and transferred to PVDF membranes (Whatman, Maidstone, UK) in transfer buffer (10% methanol, 25 mM Tris base, 192 mM glycine, PH 8.0). Membranes were incubated overnight at 4 °C with primary antibody against alpha-1-antiproteinase (Species reactivity: rat; dilution 1:1000; ab106582, Abcam, Cambridge, UK) or transferrin (Species reactivity: rat; dilution 1:10000; ab82411, Abcam, Cambridge, UK). The membranes were then washed and incubated with peroxidase-conjugated anti-chicken and anti-rabbit IgG (1:10000; zSgb-Bio, Beijing, China) at room temperature for 2 h and proteins were visualized using enhanced chemiluminescence (ECL) reagents. Intensity of each protein band was quantified using Image J analysis software (National Institutes of Health, Bethesda, Maryland, USA).

Results
=======

Urine protein-to-creatinine ratios were increased with either pentobarbital sodium or chloral hydrate anesthesia
----------------------------------------------------------------------------------------------------------------

The urinary creatinine concentrations were first reduced with anesthesia than in normal condition (in pentobarbital sodium group, creatinine decreased to 0.9-fold and in chloral hydrate group, also decreased to about 0.9-fold; [Table S1](#supp-1){ref-type="supplementary-material"}). When compared with changes of creatinine concentration, changes of urinary proteins concentrations were much more significant. As a result, the urine protein-to-creatinine values with anesthesia increased 2.4-fold (in pentobarbital sodium group, 107.1 ± 21.1 versus 259.1 ± 81.1 mg/mmol, *n* = 6, *P* value \<0.05) and 2.1-fold (in chloral hydrate group, 107.5 ± 16.5 versus 220.8 ± 79.0 mg/mmol, *n* = 6, *P* value \<0.05). With pentobarbital sodium and chloral hydrate anesthesia, the urine protein-to-creatinine ratio of all rats were significantly increased in both groups, which were consistent with the values that have been reported in previous studies ([@ref-26]; [@ref-39]). [Figure 1](#fig-1){ref-type="fig"} showed the different effects of each anesthetic on rat urine protein concentration.

![Urine protein-to-creatinine ratios before and after anesthesia (*n* = 6 each group).](peerj-03-813-g001){#fig-1}
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###### Changes in the urine proteome identified by LC-MS/MS with two anesthetics.

![](peerj-03-813-g003)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                  Pentobarbital sodium group fold change   Chloral hydrate group fold change                                   
  ------------------------------------------------- ----------------------------------------------------- ------- ---------------------------------------- ----------------------------------- ------- ------- ------- ------- -----
  [P17475](http://www.uniprot.org/uniprot/P17475)   Alpha-1-antiproteinase                                0.034   6.1↑                                     5.6↑                                8.5↑    3.4↑    8↑      3.3↑    Yes

  [P07154](http://www.uniprot.org/uniprot/P07154)   Cathepsin L1                                          0.003   2.4↓                                     3.2↓                                4↓      2.4↓    2↓      8.9↓    Yes

  [P07522](http://www.uniprot.org/uniprot/P07522)   Pro-epidermal growth factor                           0.001   2.5↓                                     2.8↓                                3.4↓    5.4↓    3.3↓    2.1↓    Yes

  [P00758](http://www.uniprot.org/uniprot/P00758)   Kallikrein-1                                          0.002   2.1↓                                     3.3↓                                3.3↓    7.5↓    2.7↓    2↓      No

  [Q5XI43](http://www.uniprot.org/uniprot/Q5XI43)   Matrix-remodeling-associated protein 8                0.006   2.8↓                                     3.1↓                                2.6↓    9.3↓    5.3↓    2.8↓    No

  [P15083](http://www.uniprot.org/uniprot/P15083)   Polymeric immunoglobulin receptor                     0.020   2.6↓                                     2.3↓                                2.2↓    3↓      2.7↓    2.8↓    No

  [P27590](http://www.uniprot.org/uniprot/P27590)   Uromodulin                                            0.006   3↓                                       5.2↓                                7↓      3.7↓    2↓      2.2↓    Yes

  [P02770](http://www.uniprot.org/uniprot/P02770)   Serum albumin                                         0.042   5.5↑                                     3.1↑                                5.4↑    --      --      --      Yes

  [P12346](http://www.uniprot.org/uniprot/P12346)   Serotransferrin                                       0.049   6.8↑                                     2.1↑                                4.3↑    --      --      --      Yes

  [P32038](http://www.uniprot.org/uniprot/P32038)   Complement factor D                                   0.046   2.2↑                                     2.4↑                                3.9↑    --      --      --      No

  [P10959](http://www.uniprot.org/uniprot/P10959)   Carboxylesterase 1C                                   0.034   3.5↑                                     3.9↑                                4.6↑    --      --      --      No

  [P20761](http://www.uniprot.org/uniprot/P20761)   Ig gamma-2B chain C region                            0.030   7.2↑                                     3.3↑                                9.1↑    --      --      --      No

  [P50123](http://www.uniprot.org/uniprot/P50123)   Glutamyl aminopeptidase                               0.044   2.1↓                                     2.5↓                                2.1↓    --      --      --      No

  [Q62867](http://www.uniprot.org/uniprot/Q62867)   Gamma-glutamyl hydrolase                              0.046   2.2↓                                     3↓                                  3.3↓    --      --      --      Yes

  [P15684](http://www.uniprot.org/uniprot/P15684)   Aminopeptidase N                                      0.039   2.4↓                                     4.4↓                                5.7↓    --      --      --      Yes

  [P26051](http://www.uniprot.org/uniprot/P26051)   CD44 antigen                                          0.006   2.9↓                                     2.5↓                                2.6↓    --      --      --      No

  [P36373](http://www.uniprot.org/uniprot/P36373)   Glandular kallikrein-7, submandibular/renal           0.021   2.1↓                                     2.2↓                                3.5↓    --      --      --      Yes

  [P98158](http://www.uniprot.org/uniprot/P98158)   Low-density lipoprotein receptor-related protein 2    0.004   2.1↓                                     3.6↓                                2.1↓    --      --      --      No

  [Q64230](http://www.uniprot.org/uniprot/Q64230)   Meprin A subunit alpha                                0.000   2.7↓                                     3.6↓                                3.4↓    --      --      --      Yes

  [P28826](http://www.uniprot.org/uniprot/P28826)   Meprin A subunit beta                                 0.031   3.5↓                                     4.9↓                                10.9↓   --      --      --      No

  [Q64319](http://www.uniprot.org/uniprot/Q64319)   Neutral and basic amino acid transport protein rBAT   0.014   2.5↓                                     2.7↓                                4.5↓    --      --      --      Yes

  [P29598](http://www.uniprot.org/uniprot/P29598)   Urokinase-type plasminogen activator                  0.048   2.5↓                                     2.2↓                                2.7↓    --      --      --      No

  [Q6DGG1](http://www.uniprot.org/uniprot/Q6DGG1)   Alpha/beta hydrolase domain-containing protein 14B    0.004   --                                       --                                  --      3.4↑    8↑      3.3↑    No

  [Q6IRK9](http://www.uniprot.org/uniprot/Q6IRK9)   Carboxypeptidase Q                                    0.037   --                                       --                                  --      2.9↑    3.6↑    4.8↑    No

  [P08649](http://www.uniprot.org/uniprot/P08649)   Complement C4                                         0.028   --                                       --                                  --      11.2↑   3.1↑    14↑     No

  [P61972](http://www.uniprot.org/uniprot/P61972)   Nuclear transport factor 2                            0.026   --                                       --                                  --      3.1↑    3.1↑    6.5↑    No

  [P02625](http://www.uniprot.org/uniprot/P02625)   Parvalbumin alpha                                     0.047   --                                       --                                  --      5.9↑    5↑      12.5↑   Yes

  [Q920A6](http://www.uniprot.org/uniprot/Q920A6)   Retinoid-inducible serine\                            0.019   --                                       --                                  --      4.2↑    4.2↑    4.7↑    No
                                                    carboxypeptidase                                                                                                                                                           

  [P82450](http://www.uniprot.org/uniprot/P82450)   Sialate O-acetylesterase                              0.016   --                                       --                                  --      5↑      9.4↑    2.4↑    No

  [P07632](http://www.uniprot.org/uniprot/P07632)   Superoxide dismutase \[Cu-Zn\]                        0.019   --                                       --                                  --      2.6↑    4.9↑    3.1↑    Yes

  [P02650](http://www.uniprot.org/uniprot/P02650)   Apolipoprotein E                                      0.032   --                                       --                                  --      2↓      5.2↓    3.3↓    No

  [Q9R0T4](http://www.uniprot.org/uniprot/Q9R0T4)   Cadherin-1                                            0.039   --                                       --                                  --      2.7↓    3.5↓    2.1↓    Yes

  [P31211](http://www.uniprot.org/uniprot/P31211)   Corticosteroid-binding globulin                       0.038   --                                       --                                  --      3.6↓    2.1↓    2.8↓    No

  [Q9JJ40](http://www.uniprot.org/uniprot/Q9JJ40)   Na(+)/H(+) exchange regulatory\                       0.047   --                                       --                                  --      3.0↓    2.7↓    3.2↓    Yes
                                                    cofactor NHE-RF3                                                                                                                                                           

  [P08460](http://www.uniprot.org/uniprot/P08460)   Nidogen-1 (Fragment)                                  0.020   --                                       --                                  --      4↓      2.5↓    4.1↓    No

  [Q63083](http://www.uniprot.org/uniprot/Q63083)   Nucleobindin-1                                        0.043   --                                       --                                  --      16.7↓   10.8↓   3.7↓    No

  [P83121](http://www.uniprot.org/uniprot/P83121)   Urinary protein 3                                     0.033   --                                       --                                  --      2.2↓    3.3↓    2.1↓    No

  [P05371](http://www.uniprot.org/uniprot/P05371)   Clusterin                                             0.040   --                                       --                                  --      5.7↓    5.8↓    2.2↓    No
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes.**

"--" means no significant changes (fold changes \>2 in all three samples).

Urinary proteome changes with anesthesia
----------------------------------------

Twelve urine samples before and after anesthesia from 6 rats (*n* = 3 in each group) in the pentobarbital sodium and chloral hydrate group were profiled by LC-MS/MS. In the pentobarbital sodium and chloral hydrate group, label-free quantitation data of proteins identified were listed in [Table S2](#supp-2){ref-type="supplementary-material"}.

In the pentobarbital sodium group, the relative abundance of 22 proteins changed according to the following criteria: fold change \>2 for each rat and *p* value \<0.05 (data were analyzed by *t* test); 6 proteins had increased relative abundance and 16 proteins had decreased relative abundance. In the chloral hydrate group, the relative abundance of 23 proteins changed: 9 proteins had increased relative abundance and 14 proteins had decreased relative abundance. Among the proteins with altered relative abundance, 7 had the same trends in all six rats that were anesthetized with either pentobarbital sodium or chloral hydrate; one protein increased relative abundance and six proteins had decreased relative abundance ([Table 1](#table-1){ref-type="table"}).

Verification of affected proteins by Western blot
-------------------------------------------------

Two changed proteins were selected to be validated in six more rats for the following reasons: (1) were identified previously in biomarker discovery; (2) were at relatively high abundance and easier to be detected in western blot; (3) had commercially available antibodies. In the pentobarbital sodium group, the levels of transferrin were analyzed and in the chloral hydrate group, the levels of alpha-1-antiproteinase were analyzed. With anesthesia, transferrin and alpha-1-antiproteinase expression levels were upregulated in three more rats ([Fig. 2](#fig-2){ref-type="fig"}), consistent with the MS quantification data.

![Semi-quantitative western blot analysis of two proteins.\
(A) Levels of urinary transferrin before and after pentobarbital sodium anesthesia. (B) Levels of urinary alpha-1-antiproteinase before and after chloral hydrate anesthesia. (C) Quantitation of the transferrin by western blot analysis from 3 independent biological replicates. (D) Quantitation of the alpha-1-antiproteinase by western blot analysis from 3 independent biological replicates \* indicates *p* \< 0.05 (data were analyzed by *t* test).](peerj-03-813-g002){#fig-2}

Comparison with previous studies
--------------------------------

In the pentobarbital sodium anesthesia group, the relative abundance of 22 proteins were changed. Compared with the Urinary Protein Biomarkers Database ([@ref-35]), 11 out of 22 proteins were considered as candidate biomarkers, such as uromodulin and serotransferrin. Among these proteins, some exhibited the opposite trend. For example, the relative abundance of aminopeptidase N was increased in septic rats with acute renal failure ([@ref-41]), whereas their relative abundance decreased with pentobarbital sodium anesthesia. In the chloral hydrate anesthesia group, the relative abundance of 23 proteins changed and chloral hydrate had a relatively different impact on the urine proteome. Compared with the Urinary Protein Biomarkers Database, 8 out of 23 proteins were considered as candidate biomarkers, such as uromodulin and parvalbumin alpha. However, the relative abundance of clusterin was increased under conditions of gentamicin administration ([@ref-37]), but it decreased with chloral hydrate anesthesia.

Rat proteins were converted to their human orthologs using the Ensembl homolog database as reported ([@ref-18]). Stable proteins in healthy human urine are more likely to become candidate biomarkers when changed ([@ref-36]). In this study, differently expressed proteins with anesthesia were compared with the human core urinary proteome, which were considered stable and relatively high in abundance. Data from the "stable urinary proteome," which represented the common and most easily identifiable proteins from urine, were determined by Mann ([@ref-27]). The dataset contains 587 proteins that were identified in each of the 7 participant's urinary proteomes on three consecutive days. The changes of high abundant proteins are likely to be real, as it is unlikely to be caused by data dependent sampling of low abundant peptides by MS. 6 out of 22 proteins (Uromodulin, Kallikrein-1, Serotransferrin, Serum albumin, Gamma-glutamyl hydrolase, Neutral and basic amino acid transport protein rBAT) affected by pentobarbital sodium had stable relative abundance in healthy human urine. Twelve out of 23 proteins (Uromodulin, Kallikrein-1, Superoxide dismutase (Cu--Zn), Putative uncharacterized protein, Parvalbumin alpha, Corticosteroid-binding globulin, E-cadherin, Alpha/beta hydrolase domain-containing protein 14B, Retinoid-inducible serine carboxypeptidase, Apolipoprotein E, Na(+)/H(+) exchange regulatory cofactor NHE-RF3, Nucleobindin-1) affected by chloral hydrate were stable. Two proteins (Uromodulin, Kallikrein-1) were shared by both groups ([Table 2](#table-2){ref-type="table"} listed the changed proteins which exist in human core urinary proteins).
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###### Changed proteins with anesthesia which exist in human stable urinary proteome and their corresponding human orthologs.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group                        Uniprot (rat)                                      Human ensembl\                       Uniprot (human)                                   Protein name                                          Related-disease
                                                                                  gene ID                                                                                                                                      
  ---------------------------- -------------------------------------------------- ------------------------------------ ------------------------------------------------- ----------------------------------------------------- -------------------------------------
  Both group                   [P27590](http://www.uniprot.org/uniprot/P27590)    [ENSG00000169344](ENSG00000169344)   [P07911](http://www.uniprot.org/uniprot/P07911)   Uromodulin                                            Fanconi Syndrome ([@ref-8])

                               [P00758](http://www.uniprot.org/uniprot/P00758)    [ENSG00000167748](ENSG00000167748)   [P06870](http://www.uniprot.org/uniprot/P06870)   Kallikrein-1                                          None

  Pentobarbital sodium group   [Q64319](http://www.uniprot.org/uniprot/Q64319)    [ENSG00000091513](ENSG00000091513)   [P02787](http://www.uniprot.org/uniprot/P02787)   Serotransferrin                                       Diabetic Nephropathy ([@ref-28])

                               [Q628 67](http://www.uniprot.org/uniprot/Q62867)   [ENSG00000163631](ENSG00000163631)   [P02768](http://www.uniprot.org/uniprot/P02768)   Serum albumin                                         Nephrotoxicity ([@ref-30])

                               [P12346](http://www.uniprot.org/uniprot/P12346)    [ENSG00000137563](ENSG00000137563)   [Q92820](http://www.uniprot.org/uniprot/Q92820)   Gamma-glutamyl hydrolase                              Uranium Nephrotoxicity ([@ref-24])

                               [P02770](http://www.uniprot.org/uniprot/P02770)    [ENSG00000138079](ENSG00000138079)   [Q07837](http://www.uniprot.org/uniprot/Q07837)   Neutral and basic amino acid transport protein rBAT   Sodium Loading ([@ref-38])

  Chloral hydrate group        [P07632](http://www.uniprot.org/uniprot/P07632)    [ENSG00000142168](ENSG00000142168)   [P00441](http://www.uniprot.org/uniprot/P00441)   Superoxide dismutase (Cu--Zn)                         Nephritis ([@ref-7])

                               [Q6IRK9](http://www.uniprot.org/uniprot/Q6IRK9)    [ENSG00000104324](ENSG00000104324)   [Q9Y646](http://www.uniprot.org/uniprot/Q9Y646)   Putative uncharacterized protein                      None

                               [P02625](http://www.uniprot.org/uniprot/P02625)    [ENSG00000100362](ENSG00000100362)   [P20472](http://www.uniprot.org/uniprot/P20472)   Parvalbumin alpha                                     Skeletal Muscle Toxicity ([@ref-9])

                               [P31211](http://www.uniprot.org/uniprot/P31211)    [ENSG00000170099](ENSG00000170099)   [P08185](http://www.uniprot.org/uniprot/P08185)   Corticosteroid-binding globulin                       None

                               [Q9R0T4](http://www.uniprot.org/uniprot/Q9R0T4)    [ENSG00000039068](ENSG00000039068)   [P12830](http://www.uniprot.org/uniprot/P12830)   E-cadherin                                            Diabetic Nephropathy ([@ref-19])

                               [Q6DGG1](http://www.uniprot.org/uniprot/Q6DGG1)    [ENSG00000114779](ENSG00000114779)   [Q96IU4](http://www.uniprot.org/uniprot/Q96IU4)   Alpha/beta hydrolase domain-containing protein 14B    None

                               [Q920A6](http://www.uniprot.org/uniprot/Q920A6)    [ENSG00000121064](ENSG00000121064)   [Q9HB40](http://www.uniprot.org/uniprot/Q9HB40)   Retinoid-inducible serine carboxypeptidase            None

                               [P02650](http://www.uniprot.org/uniprot/P02650)    [ENSG00000130203](ENSG00000130203)   [P02649](http://www.uniprot.org/uniprot/P02649)   Apolipoprotein E                                      Bladder Cancer ([@ref-21])

                               [Q9JJ40](http://www.uniprot.org/uniprot/Q9JJ40)    [ENSG00000174827](ENSG00000174827)   [Q5T2W1](http://www.uniprot.org/uniprot/Q5T2W1)   Na(+)/H(+) exchange regulatory cofactor NHE-RF3       Aldosteronism ([@ref-40])

                               [Q63083](http://www.uniprot.org/uniprot/Q63083)    [ENSG00000104805](ENSG00000104805)   [Q02818](http://www.uniprot.org/uniprot/Q02818)   Nucleobindin-1                                        None
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion
==========

Two validated changing proteins, transferrin and the alpha-1-antiproteinase, are two of the most common markers of renal diseases. Transferrin is a plasma protein that transports iron through different tissues and organs ([@ref-6]). The blood transferrin is used to determine the cause of anemia and examine iron metabolism. Urinary transferrin is upregulated in many diseases such as diabetic nephropathy, IgA nephropathy, ureteropelvic junction obstruction and bladder cancer ([@ref-35]). Alpha-1-antiproteinase can inhibit many proteases thus protects tissues from enzymes of inflammatory cells ([@ref-44]). Alpha-1-antiproteinase is also upregulated in many diseases such as kidney calculi, nephrotic syndrome, bladder cancer and focal segmental glomerulosclerosis ([@ref-35]). As these two candidate biomarkers are affected by anesthetics like pentobarbital sodium or chloral hydrate, it is necessary to exclude anesthetic related effects in future biomarker discovery studies.

Seven changed proteins shared the same trend in both groups, which could be explained by the common mechanisms of action of two general anesthetics. Pentobarbital sodium at anesthetic dose inhibits Ca^2+^-dependent release of neurotransmitters and increases the duration of Cl^−^ channel opening at the GABA~A~ receptor ([@ref-31]; [@ref-34]). Chloral hydrate also potentiates GABA-activated Cl^−^ current in central nervous system neurons by its main active metabolite trichloroethanol ([@ref-33]). The common effects of these two anesthetics on urine proteome suggest that the nervous system is possibly involved in regulation of urinary proteins. But exactly how these two anesthetics affect urinary proteins remains unknown. It may include direct and/or indirect effects on renal functions.

Central GABA receptor stimulation reduces renal sympathetic nerve discharge ([@ref-4]), which induce vasodilatation, especially in the arcuate and interlobular arteries ([@ref-20]). Central administration of GABA agonists reduce blood pressure and heart rate ([@ref-3]), which could affect renal blood flow, glomerular filtration rate, renal tubular reabsorption rate ([@ref-16]; [@ref-25]) and possibly urinary proteins.

It was proposed that GABA antagonizes the central effects of renin ([@ref-1]). The lower release of renin may consequently affect the renal sodium metabolism ([@ref-45]), which may explain why Na (+)/H (+) exchange regulatory cofactor and parvalbumin (a key protein in early distal tubule Na+ reabsorption) were affected with chloral hydrate anesthesia.

The fact that changed proteins with pentobarbital sodium and chloral hydrate anesthesia were not all the same suggested that the two anesthetics might have differences in the modes of action. Chloral hydrate also targets on the 5-HT3 receptor ([@ref-5]), which may help to explain the different effects of the two anesthetics. Previous study also showed that pentobarbital sodium anesthesia may influence hematologic values such as clotting time and partial thromboplastin time ([@ref-14]), which may explain why the kallikrein-1 and urokinase-type plasminogen activator changes with pentobarbital sodium anesthesia.

Whether these changes are influenced by anesthetic dose, the depth of the anesthesia and the time of administration require further study. The pattern of urinary proteins with altered relative abundances makes it possible to exclude interferences from anesthetics in future biomarker discovery studies. Besides, the analysis above suggests that urinary proteins may be able to reflect the functional changes as far as central nerve system. A better understanding of this mechanism will help to understand renal physiology, pathophysiology and the relationship between biomarkers and related diseases.
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###### Urinary creatinine concentrations of all samples
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Click here for additional data file.
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###### Label-free quantitation data of proteins identified in both anesthesia

\(A\) Label-free quantitation data of proteins identified in pentobarbital sodium group. (B) Label-free quantitation data of proteins identified in chloral hydrate group.
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Click here for additional data file.
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